Tetanus still caused an estimated 49,000 deaths in 2019, and 92% of them were in low and lower middle income countries. Yet the same disease has nearly collapsed in parts of the world, dropping neonatal tetanus from 787,000 deaths in 1990 to under 10,000 by 2020. How did prevention and treatment reshape outcomes so unevenly, and what do the latest case patterns look like?
Key Takeaways
- Globally, tetanus caused an estimated 49,000 deaths in 2019, with 92% occurring in low- and lower-middle-income countries
- In 2017, the global incidence of neonatal tetanus was 12,388 cases, a 97% reduction since 1988
- The United States reported only 28 cases of tetanus between 2001 and 2008, with a case-fatality rate of 13.2%
- Tetanus historically killed 1 million/year pre-vaccine; now <50,000 due to immunization
- In 1920s US, tetanus mortality was 50 per 100,000 war injuries in WWI soldiers
- Global economic burden of tetanus: $500 million/year in treatment costs in 2010
- Tetanus toxoid vaccine series provides lifelong immunity after 3 doses in 95-100%
- Neonatal tetanus prevented by maternal TT2+ vaccination, reducing risk by 94%
- DTaP vaccine 95% effective after 3 doses in children against tetanus
- Lockjaw (trismus) is the first symptom in 85-90% of generalized tetanus cases
- Generalized tetanus accounts for 80% of cases, presenting with muscle stiffness starting in jaw and neck
- Risus sardonicus (grimacing smile) occurs in 50-75% of tetanus patients due to facial muscle spasms
- Human TIG (tetanus immunoglobulin) neutralizes unbound toxin but not internalized toxin
- Metronidazole 500 mg IV q6h for 7-10 days is superior to penicillin for wound debridement
- Mechanical ventilation required in 75% of severe tetanus cases, with median duration 19 days
Tetanus still kills tens of thousands yearly, but vaccines and boosters can prevent most deaths.
Related reading
01 · Category
Epidemiology30 stats
01
Globally, tetanus caused an estimated 49,000 deaths in 2019, with 92% occurring in low- and lower-middle-income countries
02
In 2017, the global incidence of neonatal tetanus was 12,388 cases, a 97% reduction since 1988
03
The United States reported only 28 cases of tetanus between 2001 and 2008, with a case-fatality rate of 13.2%
04
In India, tetanus accounts for 15-20% of neonatal mortality in unvaccinated populations
05
Africa reported 49% of global neonatal tetanus cases in 2015 despite comprising 28% of global births
06
Between 1990 and 2017, global tetanus mortality decreased by 89% due to vaccination efforts
07
In Ethiopia, the incidence of neonatal tetanus was 0.4 per 1,000 live births in 2016
08
Bangladesh achieved elimination of maternal and neonatal tetanus in 2016 after reporting 2,518 cases in 1982
09
In sub-Saharan Africa, tetanus incidence is highest among males aged 20-40 years due to agricultural injuries
10
Pakistan reported 4,200 neonatal tetanus cases annually in the early 2000s, now reduced to under 1,000 by 2020
11
The WHO estimates 34,000 neonatal tetanus deaths worldwide in 2015, primarily in South Asia and sub-Saharan Africa
12
In the US, 94% of tetanus cases from 2001-2016 occurred in unvaccinated or inadequately vaccinated individuals
13
Nigeria accounted for 20% of global neonatal tetanus cases in 2008 before elimination efforts
14
In Indonesia, tetanus vaccination coverage reached 96% by 2019, reducing cases by 85% since 2000
15
Europe reported fewer than 100 tetanus cases annually since 2000, with Italy having the highest at 20-30/year
16
In Yemen, conflict led to a 300% increase in neonatal tetanus cases from 2015-2019
17
Australia had 47 tetanus cases from 1993-2007, with 10 deaths, mostly in elderly unvaccinated
18
In Brazil, tetanus incidence dropped from 0.14 to 0.03 per 100,000 from 2000-2015
19
South-East Asia region saw neonatal tetanus cases fall from 100,000 in 1990 to 4,900 in 2016
20
In Kenya, neonatal tetanus incidence was 1.8 per 1,000 live births in high-risk districts in 2010
21
Globally, 80% of tetanus deaths occur in children under 5 years
22
In the UK, there were 11 tetanus cases from 2000-2017, all vaccine-preventable
23
Afghanistan reported 5,000 neonatal tetanus cases in 2009, reduced by 90% by 2020
24
In Somalia, tetanus remains endemic with 1,200 neonatal cases estimated in 2018
25
China eliminated maternal and neonatal tetanus in 2017 after 1 million cases historically
26
In the Democratic Republic of Congo, tetanus incidence is 0.5 per 100,000 population annually
27
Mexico reported zero neonatal tetanus cases since 2015, achieving elimination status
28
In Thailand, tetanus cases decreased from 200 in 1990 to 20 in 2018
29
Uganda validated elimination of maternal and neonatal tetanus in 2019 after 1,000 annual cases in 2000s
30
Worldwide, tetanus spores contaminate 1-2% of soil samples in temperate climates
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, tetanus mortality has fallen sharply with vaccination, dropping by 89% between 1990 and 2017, while deaths remain concentrated in low- and lower-middle-income countries where 92% of the estimated 49,000 deaths in 2019 still occur.
02 · Category
Historical And Economic Impact24 stats
01
Tetanus historically killed 1 million/year pre-vaccine; now <50,000 due to immunization
02
In 1920s US, tetanus mortality was 50 per 100,000 war injuries in WWI soldiers
03
Global economic burden of tetanus: $500 million/year in treatment costs in 2010
04
Neonatal tetanus caused 787,000 deaths in 1990, now <10,000 by 2020
05
Vaccine development: Descombey purified toxoid in 1924, licensed 1938
06
WWII tetanus incidence 0.04% in vaccinated vs 1-2% unvaccinated troops
07
India spent $100 million on MNT campaigns 2000-2015, averting 150,000 deaths
08
Pre-vaccine era Europe: 1,000 tetanus deaths/year in UK alone 1930s
09
Cost-effectiveness: DTP vaccine $25/DALY averted vs tetanus treatment $1,000+
10
Haiti earthquake 2010: 50 tetanus cases, 24 deaths without prophylaxis
11
Historical case-fatality 90% pre-antitoxin 1890s, now 10-20%
12
Global Alliance for Vaccines saved 25M lives from tetanus since 2000, $1.5B invested
13
In 1980s Africa, tetanus 20% of child ICU admissions, now <1%
14
US tetanus deaths: 1,314 in 1947 to 28 total 2001-2017
15
Economic loss per neonatal tetanus death: $5,000in low-income countries
16
Behring Nobel 1901 for tetanus antitoxin discovery 1890
17
Bangladesh MNT program 1980s-2016: 90% case reduction, $50M cost
18
Post-WWII toxoid boosters every 10y policy reduced cases 99%
19
Yemen civil war 2015+: tetanus cases up 400%, $10M emergency response
20
Historical incubation knowledge from war wounds: 4-21 days average 8
21
GAVI Alliance funded 400M TT doses 2001-2020, averting 500,000 deaths
22
Australia 1940s: 50 deaths/year to 0-2/year now
23
Disability-adjusted life years from tetanus: 1.2M in 1990 to 0.1M in 2019
24
China 1950s: 20,000 cases/year to elimination 2017, $200M vaccination effort
Interpretation
Historical And Economic Impact Interpretation
Historically tetanus killed about 1 million people per year and in the 1990s still caused 787,000 neonatal deaths, but global immunization has driven deaths below 10,000 by 2020 and cut annual treatment costs to about $500 million since 2010, showing a dramatic historical and economic shift from widespread fatal burden to largely preventable disease.
03 · Category
Prevention And Vaccination24 stats
01
Tetanus toxoid vaccine series provides lifelong immunity after 3 doses in 95-100%
02
Neonatal tetanus prevented by maternal TT2+ vaccination, reducing risk by 94%
03
DTaP vaccine 95% effective after 3 doses in children against tetanus
04
Booster Td/Tdap every 10 years maintains anti-tetanus IgG >0.1 IU/mL in 90%
05
Clean delivery practices reduce neonatal tetanus by 89% in home births
06
152 countries eliminated maternal/neonatal tetanus by 2022 via vaccination campaigns
07
Tdap in pregnancy (27-36 weeks) prevents 90% of neonatal cases via passive immunity
08
Wound management with TIG prophylaxis prevents 100% of tetanus in high-risk dirty wounds
09
Global TT vaccine coverage in women of childbearing age reached 80% by 2019
10
School-based DTP3 coverage >90% correlates with zero tetanus cases nationally
11
Post-exposure prophylaxis: TIG + vaccine booster protects 99% if given <24h injury
12
Hygiene education in rural areas reduces injury-related tetanus by 70%
13
HPV/Tdap co-administration safe, with 92% seroprotection for tetanus
14
Animal bite prophylaxis includes TT booster if >5 years since last dose
15
MNT elimination requires 85%+ TT2+ coverage in women 15-49 years annually
16
Adverse events after Tdap: local reactions 60-70%, systemic 10-20%, anaphylaxis 1/million
17
Earthquake disasters see 10-fold tetanus rise without mass vaccination
18
Universal vaccination policy in US since 1940s reduced cases from 500+/year to <30
19
Conjugate vaccines (DTaP) 98% effective vs tetanus in 5-year follow-up
20
Community immunization days in Afghanistan vaccinated 20M, cutting neonatal cases 90%
21
Tetanus vaccine shelf-life 24 months at 2-8°C, potency loss <5% if cold chain intact
22
IVDU tetanus prevented by harm reduction education + vaccination uptake 75%
23
Economic analysis: TT vaccination costs $1.50/dose, saves $200/neonatal case avoided
24
Reflex testing for anti-tetanus antibodies in elderly shows 40% immunity gap
Interpretation
Prevention And Vaccination Interpretation
Across prevention and vaccination efforts, Tetanus protection is highly effective and lasting, with 3-dose toxoid or DTaP schedules delivering 95 to 100 percent or 95 percent effectiveness and boosters keeping IgG above 0.1 IU/mL in 90 percent, while maternal TT2+ vaccination and clean delivery practices cut neonatal tetanus by 94 percent and 89 percent leading 152 countries to eliminate maternal or neonatal tetanus by 2022.
More related reading
04 · Category
Symptoms And Diagnosis26 stats
01
Lockjaw (trismus) is the first symptom in 85-90% of generalized tetanus cases
02
Generalized tetanus accounts for 80% of cases, presenting with muscle stiffness starting in jaw and neck
03
Risus sardonicus (grimacing smile) occurs in 50-75% of tetanus patients due to facial muscle spasms
04
Opisthotonos (severe arching of back) is seen in 70% of severe generalized tetanus cases
05
Autonomic dysfunction, including hypertension and tachycardia, affects 70-80% of ICU-admitted tetanus patients
06
Cephalic tetanus, involving cranial nerves, occurs in 1-3% of cases, often post-head injury
07
Neonatal tetanus presents with inability to suck or cry normally within 3-14 days of birth
08
Localized tetanus affects 1-5% of cases, with persistent stiffness at injury site for months
09
Hyperthermia (>38.5°C) is present in 60% of tetanus cases due to muscle hyperactivity
10
Difficulty swallowing (dysphagia) occurs in 65% of generalized tetanus patients
11
Reflex spasms triggered by stimuli affect 90% of patients, lasting 30 seconds to minutes
12
Serum anti-tetanus IgG levels <0.01 IU/mL confirm susceptibility in diagnosis
13
CSF in tetanus shows normal cell count and protein in 95% of cases, aiding differential diagnosis
14
Electromyography (EMG) reveals continuous motor unit activity in tetanus muscles
15
Abdominal rigidity is an early sign in 40% of cases, preceding limb involvement
16
Laryngospasm occurs in 20-50% of severe cases, risking airway obstruction
17
Piloerection and diaphoresis are autonomic signs in 75% of hospitalized patients
18
Incubation period averages 7-10 days, shorter (<3 days) indicating higher severity
19
Period of onset (from first symptom to spasms) <48 hours predicts 100% mortality without ICU
20
Nuchal rigidity mimics meningitis but lacks fever or CSF pleocytosis in tetanus
21
Ocular findings include sluggish pupils and poor convergence in 30% of cases
22
Urinary retention due to sphincter spasm affects 50% of patients
23
Verner-Morrison syndrome (hypotension, bradycardia) rare in 5% of severe cases
24
Sialorrhea (excessive salivation) in 40% due to inability to swallow
25
Tachyphylaxis to benzodiazepines develops in 80% of patients after 3-5 days
26
Culture-positive C. tetani from wounds in only 30% of clinically diagnosed cases
Interpretation
Symptoms And Diagnosis Interpretation
In the symptoms and diagnosis category, lockjaw appears first in 85 to 90 percent of generalized tetanus cases and, along with the high rates of risus sardonicus and opisthotonos in generalized and severe disease, it makes early jaw and facial or postural signs a major diagnostic clue.
05 · Category
Treatment And Outcomes25 stats
01
Human TIG (tetanus immunoglobulin) neutralizes unbound toxin but not internalized toxin
02
Metronidazole 500 mg IV q6h for 7-10 days is superior to penicillin for wound debridement
03
Mechanical ventilation required in 75% of severe tetanus cases, with median duration 19 days
04
Case-fatality rate for generalized tetanus is 10-20% with modern ICU care
05
Intrathecal TIG (250-500 IU) reduces mortality by 50% compared to IM in some studies
06
Magnesium sulfate infusion controls spasms better than diazepam in 60% of patients
07
Neuromuscular blockade with vecuronium needed in 50% for ventilator synchrony
08
Survival rate in neonatal tetanus is <10% without intensive care
09
Antibiotic therapy reduces bacterial load but does not affect outcome if TIG given early
10
Active immunization with TT vaccine during recovery prevents future episodes in 95%
11
Beta-blockers (atenolol) reduce autonomic instability mortality from 21% to 8%
12
Wound excision within 24 hours decreases incubation-to-onset period impact on severity
13
Propofol sedation allows faster weaning than benzodiazepines, reducing ICU stay by 5 days
14
Mortality in localized tetanus is <1%, vs 50-60% in untreated generalized
15
Equine tetanus antitoxin used when human TIG unavailable, but 5-10% anaphylaxis risk
16
Tracheostomy performed in 80% of ventilated patients to prevent aspiration
17
Recovery phase spasms persist 2-4 weeks, with full strength return in 4-6 weeks
18
Nosocomial pneumonia complicates 30% of ICU tetanus cases, increasing mortality 2-fold
19
IVIG (400 mg/kg) as alternative to TIG neutralizes toxin effectively in 90%
20
Fosphenytoin for refractory spasms controls seizures in 70% without intubation escalation
21
Nutritional support via NG tube required in 90% due to dysphagia >2 weeks
22
DVT prophylaxis with LMWH prevents clots in 95% of immobilized patients
23
Case-fatality in cephalic tetanus is 15-50% due to rapid bulbar involvement
24
Baclofen intrathecal infusion reduces spasm frequency by 80% in refractory cases
25
Overall ICU mortality for tetanus 20-30%, highest in >60 years old at 40%
Interpretation
Treatment And Outcomes Interpretation
For treatment and outcomes in tetanus, modern ICU care has brought generalized case fatality down to about 10 to 20 percent, while 75 percent of severe cases still require mechanical ventilation for a median of 19 days, underscoring both the progress in survival and the ongoing critical care burden.
report visual · Key figures
Tetanus deaths have fallen sharply with vaccination
Global tetanus mortality has dropped dramatically over time, driven by vaccination efforts and improved prevention.
89%
Between 1990 and 2017, global tetanus mortality decreased by 89% due to vaccination efforts
92%
Globally, tetanus caused an estimated 49,000 deaths in 2019, with 92% occurring in low- and lower-middle-income countrie
34,000
The WHO estimates 34,000 neonatal tetanus deaths worldwide in 2015, primarily in South Asia and sub-Saharan Africa
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Tetanus Statistics. Gitnux. https://gitnux.org/tetanus-statistics
MLA
James Okoro. "Tetanus Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/tetanus-statistics.
Chicago
James Okoro. 2026. "Tetanus Statistics." Gitnux. https://gitnux.org/tetanus-statistics.
Sources & references
22 datasets cited across this report · attribution is report-level